SPECIAL 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION
DECISION SUMMARY

I Background Information:

A 510(k) Number

K202739

B Applicant

Bioland Technology Ltd.

C Proprietary and Established Names

Bioland G-425-2V Blood Glucose Monitoring System, Bioland G-425-2 Blood Glucose Monitoring System

D Regulatory Information

Product Code(s)	Classification	Regulation Section	Panel
NBW	Class II	21 CFR 862.1345 - Glucose Test System	CH - Clinical Chemistry

II Review Summary:

This 510(k) submission contains information/data on modifications made to the submitter's own CLASS II device requiring 510(k). The following items are present and acceptable.

1. The name and 510(k) number of the SUBMITTER'S previously cleared device: Bioland Blood Glucose Monitoring System, K191657.

2. Submitter's statement that the **INDICATIONS FOR USE/INTENDED USE** of the modified device as described in its labeling **HAS NOT CHANGED** along with the proposed labeling which includes instructions for use, package labeling, and, if available, advertisements or promotional materials (labeling changes are permitted as long as they do not affect the intended use).

3. A description of the device **MODIFICATION(S)**, including clearly labeled diagrams, engineering drawings, photographs, user's and/or service manuals in sufficient detail to demonstrate that the **FUNDAMENTAL SCIENTIFIC TECHNOLOGY** of the modified

device **has not changed.** This change was for creating two device systems from the predicate device and included:

- A change to the device trade name from Bioland Blood Glucose Monitoring System to Bioland G-425-2 Blood Glucose Monitoring System and Bioland G-425-2V Blood Glucose Monitoring System.

- The removal of the Bluetooth function from both meters.

- The addition of a voice function to the G-425-2V meter that speaks the result after each blood glucose and control solution test.

4. Comparison Information (i.e., similarities and differences) to the submitter's legally marketed predicate device including labeling, intended use, and physical characteristics.

5. A Design Control Activities Summary which includes:

   a) Identification of Risk Analysis method(s) used to assess the impact of the modification on the device and its components, and the results of the analysis.

   b) Based on the Risk Analysis, an identification of the verification and/or validation activities required, including methods or tests used and acceptance criteria to be applied.

The labeling for this modified subject device has been reviewed to verify that the indication/intended use for the device is unaffected by the modification. In addition, the submitter's description of the particular modification(s) and the comparative information between the modified and unmodified devices demonstrate that the fundamental scientific technology has not changed. The submitter has provided the design control information as specified in The New 510(k) Paradigm and on this basis, I recommend the device be determined substantially equivalent to the previously cleared (or their preamendment) device.

The device systems are intended for single-patient use only. Disinfection efficacy studies were previously performed (K191657) with the external meter materials by an outside commercial testing laboratory demonstrating complete inactivation of hepatitis B virus (HBV) with Clorox Healthcare Bleach Germicidal Wipes (EPA Reg. No: 67619-12). The sponsor also conducted robustness studies demonstrating that there was no change in performance or in the external materials of the meter after 3,650 cleaning and disinfection cycles using the chosen wipe representing 5 years of single patient use. Labeling was reviewed for adequate instructions for the validated cleaning and disinfection procedures.